---

Image

---

X (formerly Twitter):  #Conversations on Cancer 
 Sponsored by the U.S. Food & Drug Administration (FDA)

Registration required to attend:  https://www.surveymonkey.com/r/FTYFN3H

Background: 

The FDA Oncology Center of Excellence (OCE) Conversations on Cancer public panel discussion series event on January 10, 2024, will highlight oncology drug approvals in 2023. We will review a wide range of cancers, approval of novel drugs, and new uses for previously approved drugs. The discussion will focus on the most transformative oncology drug approvals for 2023 and showcase OCE’s commitment to protecting and advancing patient care through approval of life-altering treatments for cancer patients.  

This panel discussion will feature a diverse group of speakers including patients/advocates, clinical investigators and practitioners who will discuss their experiences with these transformative drugs for cancer patients. 
Important issues we plan to discuss include:

• Patient and investigator perspectives on their experiences with these drugs, including importance of timely access to these drugs.
• Patient perspectives on the impact of these drugs on their cancer prognosis and quality of life.
• Investigators’ perspectives on the impact of these drugs on their respective cancer landscape and treatment paradigm for the specified cancer indication(s). 
• Barriers to access of these newly approved drugs and ways to help overcome these barriers.

Webcast Information: 

A free-of-charge webcast of this public panel discussion will be provided. Registration for the webcast is required at the link above. 
FDA plans to post archived webcast of this Conversations on Cancer program at: https://www.fda.gov/about-fda/project-community/conversations-cancer

Contact:

For any inquiries regarding this program, please send an email to: OCE-Engagement@fda.hhs.gov